Transparency
Market Research (TMR) has published a new report titled, ‘Caspofungin Market -
Global Industry Analysis, Size, Share, Growth, Trends, and Forecast,
2019–2027.’ According to the report, the global caspofungin
market was valued at US$ 484.20 Mn in 2018 and is projected to
expand at a CAGR of 0.18% from 2019 to 2027. Rise in prevalence of chronic
diseases such as cancer and diabetes, increase in the geriatric population, and
surge in awareness about advanced therapies are factors anticipated to propel
the global caspofungin market from 2019 to 2027.
Request Brochure –
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=64311
The
global population is aging rapidly. According to the WHO, nearly 2 billion
people are expected to be aged 60 and above by 2050, accounting for 16.7% of
the global population. The population in developed countries such as those in
Western Europe, Japan, and the U.S. is aging at a rapid pace. Invasive fungal
infections have become an increasing problem in older adults. Opportunistic
fungal infections have increased in older patients because they are more likely
to receive transplanted solid organs or bone marrow, undergo aggressive
treatment of malignancies, and take immunosuppressive medications for
dermatologic and rheumatologic diseases. Compared to young patients, older
patients are less able to handle invasive endemic or opportunistic infections,
and outcomes of infection are frequently worse for elder patients. Increase in the
geriatric population is expected to be a major factor likely to augment the
global market during the forecast period.
Request COVID Analysis on Caspofungin
Market –
https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=64311
The report offers detailed
segmentation of the global caspofungin market based on indication, distribution
channel, and region. In terms of indication, the candidiasis segment is
anticipated to account for large market share due to increase in applications
of echinocandins in candidiasis and benefits of echinocandins over other
antifungals. The benefits of echinocandins include low risk of drug-drug
interactions, novel mechanism of action, and lesser adverse effects.
Echinocandins demonstrate compelling activity against Candida species
and are the preferred first-line therapy for patients with invasive
candidiasis. It has been reported that more than 60% of candidemia patients
receive echinocandin during therapy.
Request Customization on Caspofungin Market Report –
https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=64311
Hospital Pharmacies Segment to Account for Major Share
The
hospital pharmacies segment is projected to account for leading share of the
global market by 2027. Rise in prevalence of mycosis in the elderly population
has increased the number of hospital visits. This in turn is likely to boost
the growth of the segment.
North
America Market to Expand at Rapid Pace
North
America held major share of the global market in terms of revenue in 2018 and
is projected to sustain its position during the forecast period. High awareness
about latest health care technologies and higher purchasing power are
attributed to the larger market share of the region. Favorable reimbursement
policies in the region also enable patients to avail the best health care
facilities. Europe is anticipated to be the second largest market in terms of
share and revenue during the forecast period. Developed health care
infrastructure in the region has helped patients undergoing therapies in
covering their expenditure. Most health care providers in countries such as
Germany, the U.K., and France provide full or partial coverage of costs related
to treatment, medication, physicians cost, and tests depending on the patient’s
insurance plan and income.
Buy Caspofungin Market Report –
https://www.transparencymarketresearch.com/checkout.php?rep_id=64311<ype=S
Merck & Co., Inc., Mylan N.V.,
and Fresenius SE & Co. KGaA to Lead Global Market
The
report also provides profiles of leading players operating in the global
caspofungin market. These include Teva Pharmaceutical Industries Ltd., Gland
Pharma Limited, and Xellia Pharmaceuticals.
About
Us
Transparency
Market Research (TMR) is a market intelligence company, providing global
business information reports and services. Our exclusive blend of quantitative
forecasting and trends analysis provides forward-looking insight for thousands
of decision makers. We have an experienced team of Analysts, Researchers,
and Consultants, who use proprietary data sources and various tools and
techniques to gather, and analyze information. Our business offerings represent
the latest and the most reliable information indispensable for
businesses to sustain a competitive edge.
Each
TMR Syndicated Research report covers a different sector — such as
pharmaceuticals, chemical, energy, food & beverages, semiconductors,
med-devices, consumer goods and technology. These reports provide in-depth
analysis and deep segmentation to possible micro levels. With wider scope and
stratified research methodology, our syndicated reports thrive to provide
clients to serve their overall research requirement.
Contact
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/
